Schering-Plough products approved and launched in Japan
This article was originally published in Scrip
Executive Summary
Schering-Ploughhas received formal approval in Japan for its once-daily intranasal steroid Nasonex (mometasone furoate monohydrate), for adult allergic rhinitis. The product will be the first of its type in the country, where the disorder affects 18-23 million people, the company noted. It was recommended in May (Scrip Online, May 29th, 2008) and a launch after price listing is expected in the autumn. Aroglycem (diazoxide) for hyperinsulinism, which received a priority review, has just been launched and is reimbursed at ¥251.80 ($2.36) per 25mg capsule.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.